The Federal Circuit Upholds Drug Dosing Regimen as Valid and Nonobvious

In Janssen Pharmaceuticals, Inc. v. Mylan Laboratories., the United States Court of Appeals for the Federal Circuit affirmed a district court ruling that a pharmaceutical dosing claim limitation was nonobvious despite prior art describing dosing regimens for the same active ingredient….
By: DLA Piper